Tag: rising-biotech

(Reuters) – Belgian biotech firm Ablynx said on Thursday it used up more cash than it made in the first quarter, driven by higher external research and development costs. Cash burn is a closely watched figure for rising biotech companies that generate revenue only from development milestone payments, and not drug sales. The group, which…